Hidetaka Yamamoto1, Akihiko Yoshida2, Kenichi Taguchi3, Kenichi Kohashi1, Yui Hatanaka1, Atsushi Yamashita4, Daisuke Mori5, Yoshinao Oda1. 1. Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 2. Department of Pathology and Clinical Laboratories, National Cancer Centre Hospital, Tokyo, Japan. 3. Department of Pathology, National Kyushu Cancer Center, Fukuoka, Japan. 4. Department of Pathology, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan. 5. Department of Pathology, Saga Medical Centre Koseikan, Saga, Japan.
Abstract
AIMS: The aim of this study was to elucidate the pathological features of inflammatory myofibroblastic tumour (IMT) with gene rearrangement other than ALK. METHODS AND RESULTS: We investigated anaplastic lymphoma kinase (ALK), ROS1, ETV6, NTRK3 and RET in 36 cases of IMT by using immunohistochemical (IHC) staining, fluorescence in-situ hybridization, and reverse transcription polymerase chain reaction (RT-PCR). IHC staining showed ALK and ROS1 to be positive in 22 of 36 (61.1%) and two of 36 (5.6%) cases, respectively. In one case with ROS1 positivity, IHC staining showed cytoplasmic and dot-like ROS1 expression, and RT-PCR showed the presence of the TFG-ROS1 fusion transcript. Two cases of pulmonary IMT, in a 7-year-old patient and a 23-year-old patient, had ETV6 rearrangement, and the presence of the ETV6-NTRK3 fusion transcript was confirmed in one case. These tumours were composed of hypocellular myxoid areas and highly cellular areas with rich plasmacytic infiltration; the histological features were different from those of infantile fibrosarcoma. RET rearrangement was not detected. CONCLUSIONS: These results suggest that a subset of ALK-negative IMTs have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism, and that the detection of these alterations may be of diagnostic value and helpful for determining promising therapeutic strategies.
AIMS: The aim of this study was to elucidate the pathological features of inflammatory myofibroblastic tumour (IMT) with gene rearrangement other than ALK. METHODS AND RESULTS: We investigated anaplastic lymphoma kinase (ALK), ROS1, ETV6, NTRK3 and RET in 36 cases of IMT by using immunohistochemical (IHC) staining, fluorescence in-situ hybridization, and reverse transcription polymerase chain reaction (RT-PCR). IHC staining showed ALK and ROS1 to be positive in 22 of 36 (61.1%) and two of 36 (5.6%) cases, respectively. In one case with ROS1 positivity, IHC staining showed cytoplasmic and dot-like ROS1 expression, and RT-PCR showed the presence of the TFG-ROS1 fusion transcript. Two cases of pulmonary IMT, in a 7-year-old patient and a 23-year-old patient, had ETV6 rearrangement, and the presence of the ETV6-NTRK3 fusion transcript was confirmed in one case. These tumours were composed of hypocellular myxoid areas and highly cellular areas with rich plasmacytic infiltration; the histological features were different from those of infantile fibrosarcoma. RET rearrangement was not detected. CONCLUSIONS: These results suggest that a subset of ALK-negative IMTs have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism, and that the detection of these alterations may be of diagnostic value and helpful for determining promising therapeutic strategies.
Authors: Iwei Yeh; Meng Kian Tee; Thomas Botton; A Hunter Shain; Alyssa J Sparatta; Alexander Gagnon; Swapna S Vemula; Maria C Garrido; Kenji Nakamaru; Takeshi Isoyama; Timothy H McCalmont; Philip E LeBoit; Boris C Bastian Journal: J Pathol Date: 2016-11 Impact factor: 7.996
Authors: Jason C Chang; Lei Zhang; Alexander E Drilon; Ping Chi; Rita Alaggio; Laetitia Borsu; Ryma Benayed; William D Travis; Marc Ladanyi; Cristina R Antonescu Journal: J Thorac Oncol Date: 2018-12-11 Impact factor: 15.609
Authors: Brendan C Dickson; David Swanson; George S Charames; Christopher Dm Fletcher; Jason L Hornick Journal: Mod Pathol Date: 2018-01-12 Impact factor: 7.842
Authors: Martin S Taylor; Abhijit Chougule; Allsion R MacLeay; Pawel Kurzawa; Ivan Chebib; Long Le; Vikram Deshpande Journal: Am J Surg Pathol Date: 2019-03 Impact factor: 6.394